Erasmus University Rotterdam is a renowned public university located in Rotterdam, the Netherlands, in the city that also houses the largest port in Europe. The university is named after Desiderius Erasmus Roterodamus, a 15th-century humanist and theologian. Erasmus for centuries has enjoyed popularity in academia, being a person who should always be remembered by Rotterdam.Erasmus University Rotterdam has been among the best in all kinds of world rankings. In 2007, Erasmus University Rotterdam ranked top ten of the top universities in Europe by " Financial Times ". In 2014, Erasmus University Rotterdam is ranked by Times Higher Education as 20th in Europe and 73rd in the world, with its social science as 47th, and clinical and health as 37th in the world.The university has seven faculties and focuses on four areas of expertise.Health - Faculty of Medicine and Health science/Erasmus MC and institute of Health Policy & Management Wealth - Erasmus School of Economics and Rotterdam School of Management, Erasmus UniversityGovernance - Erasmus School of Law and Faculty of Social scienceCulture - Erasmus School of History, Culture and Communication, Faculty of Social science and Faculty of PhilosophyErasmus MC is the largest and one of the foremost academic medical centers and trauma centers in the Netherlands, whereas its economics and business school, Erasmus School of Economics and Rotterdam School of Management, Erasmus University are leading economics school and business school within Europe and the world. Wikipedia.
Erasmus University Rotterdam and Skylinedx B.V. | Date: 2017-02-01
The invention is in the field of medical treatments and relates to the treatment of cancer, in particular multiple myeloma (MM). Even more in particular it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular subjects with a poor prognosis. In a particular embodiment, the invention provides a method of treatment wherein subjects with a poor prognosis are selected and treated with a proteasome inhibitor such as Bortezomib. The invention further provides means and methods for identifying subjects with a poor prognosis. More in particular, the invention provides a composition comprising a proteasome inhibitor for use in the treatment of a subject with multiple myeloma wherein the subject has been diagnosed with an amp1q chromosomal aberration.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.91M | Year: 2017
The EU currently is negotiating a controversial Transatlantic Trade and Investment Partnership (TTIP) agreement with the USA, the main features of which will be the abolition of tariffs, the reduction of non-tariff barriers to trade between the EU and the USA and the introduction of a dispute settlement mechanism. The objective of the proposed TTIP Innovative Training Network (TTIP-ITN) is to foster interdisciplinary research into TTIP with a view to create a significantly increased European knowledge base and research capacity on TTIP, thus helping Europe to reap the benefits of TTIP (wealth, jobs, etc.) while addressing its challenges (democracy, accountability, environmental- and labour standards, etc.).The network is an interdisciplinary, intersectoral collaboration pooling world-leading researchers and practitioners from all relevant disciplines of law - EU constitutional, internal market, and external relations law, international trade law, and international law, as well as political science, international relations, business studies, and economics. TTIP-ITN fully integrates non-academic Beneficiaries and Partner Organisations, including think tanks, lobbyists, regulatory bodies, law firms, US academic institutions, and an international organisation. Furthermore, the network will support and enhance the process of converting research results into policy papers through partnership with high-impact policy research units at the forefront of European policy research and policy making. The work package consists of 3 substantive work packages on (1) transatlantic governance, (2) transatlantic regulation, and (3) multilateralism and regionalism. 15 PhD research projects will be supervised by academics of the 11 Beneficiaries with an interdisciplinary training programme covering the legal, political and economic foundations of TTIP and an interdisciplinary and intersectoral programme of secondments involving 22 Partner Organisations.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: SCC-1-2016-2017 | Award Amount: 19.56M | Year: 2016
The RUGGEDISED project will create urban spaces powered by secure, affordable and clean energy, smart electro-mobility, smart tools and services. The overall aims are: 1. Improving the quality of life of the citizens, by offering the citizens a clean, safe, attractive, inclusive and affordable living environment. 2. Reducing the environmental impacts of activities, by achieving a significant reduction of CO2 emissions, a major increase in the investment and usage of RES and an increase in the deployment of electric vehicles. 3. Creating a stimulating environment for sustainable economic development, by generating more sustainable jobs, stimulating community involvement in smart solutions and to boost start-up and existing companies to exploit the opportunities of the green digital economy and Internet of Things. To achieve the aims, a key innovation challenge in all three lighthouse cities of RUGGEDISED is to arrange successful combinations of integrated smart solutions for energy and e-mobility (enabled by ICT platforms and open data protocols) and business models with the right incentives for stakeholders to invest and participate in a smart society. Specific challenges relevant for the lighthouse cities are: - to manage peak load variation in thermal and electrical energy supply and demand; - to develop appropriate cooperation structures and business models for exchange of energy; - to develop Smart City (open) data platforms and energy management systems RUGGEDISED has derived 10 specific objectives and planned 32 smart solutions to meet the challenges. The development of solutions in the lighthouse cities is not the primary goal of the project, but a necessary means to find the right incentives and to create validated business cases to enable large scale deployment and replication of solutions. Three follower cities Brno, Parma and Gdansk have selected 27 smart follower solutions to follow the lighthouse cities and to prepare for implementation in the future
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-11-2015 | Award Amount: 6.44M | Year: 2016
The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technology combining Spectral Photon Counting CT and contrast agents, to accurately and early detect, characterize and monitor neurovascular and cardiovascular disease. Spectral Photon Counting Computed Tomography (SPCCT) is a new imaging modality, currently in development, with a totally new type of detection chain designed to provide high count-rate capabilities while offering energy discrimination with high spatial resolution of 200m. Based on this discrimination, SPCCT can detect and quantify accurately a large variety of atoms (including Gadolinium, Gold, Bismuth) by using the K-edge technique. SPCCT, by a more accurate, less invasive (in comparison with IVUS and coronary angiography) and reliable evaluation of vascular inflammation will allow earlier disease diagnosis such as plaque inflammation before rupture, leading to improved clinical decisions and outcomes. This will be achievable with a high spatial resolution combined to the newly developed vascular inflammation specific contrast agent detected with high quality K-edge technique that can only be provided by a multi-spectral X-ray system. The project will therefore provide a complete tool (acquisition system and specific probes) dedicated to CV imaging. It will finally contribute to: Improved early diagnosis of atherosclerosis, prevention of acute event (MI, stroke) and personalized preventive treatment; Improved management of patient presenting with an acute CV event and clinical validation of treatment efficiency; Sustainability and harmonization of healthcare systems, as costly disorders of heart failure and stroke-related disability would be better prevented and efficiently treated; Economic growth in the EU diagnostics sector, through the development of new targeted contrast materials for SPCCT by SMEs.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-09-2016 | Award Amount: 6.23M | Year: 2017
Optogenerapy proposes a new interferon- (IFN-) drug delivery system to revolutionize Multiple Sclerosis treatment. The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics light controlling the cellular response of genetically engineered cells is used to control the production of IFN-. Replacing standard intravenous IFN- delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs. It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness. The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014s big advances in science. In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands. BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: MG-6.3-2015 | Award Amount: 17.72M | Year: 2016
SELIS is aimed at delivering a platform for pan-European logistics applications by: - Embracing a wide spectrum of logistics perspectives and creating a unifying operational and strategic business innovation agenda for pan European Green Logistics. - Establishing an exceptionally strong consortium of logistics stakeholders and ICT providers, that can leverage EU IP from over 40 projects so as to create proof of concept Common Communication and navigation platforms for pan-European logistics applications in month 18 deployed in 8 living labs (LLs) representing the principal logistics communities. - Establishing a research and innovation environment using the LLs to provide data than can be used for discovery of new insights that will enable continuous value creation supporting the large scale adoption of SELIS. The proposed Shared European Logistics Intelligent Information Space, SELIS, is a network of logistic communities specific shared intelligent information spaces termed SELIS Community Nodes (SCN). SCNs are constructed by individual logistics communities to facilitate the next generation of collaborative, responsive and agile green transportation chains. SCNs link with their participants existing systems through a secure infrastructure and provide shared information and tools for data acquisition and use, according to a cooperation agreement. Connected nodes, provide a distributed common communication and navigation platform for Pan European logistics applications. Each Node decides what information wishes to publish and what information wants to subscribe to. The SELIS Community Node (SCN) concept represents the evolution of a longline of research in this area. The fundamental principle is that it provides a lightweight ICT structure to enable information sharing for collaborative sustainable logistics for all at strategic and operational levels.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.88M | Year: 2017
Improving quality of care has been given too little attention in health economic research in the past although it is the central goal of health care systems in Europe. The proposed ETN on Improving Quality of Care in Europe (IQCE) aims to address this gap and has the following aims: 1) Create new evidence and improve existing health economic research in the field of quality of care. Research gaps are addressed by empirical, theoretical and experimental approaches with a focus on innovative econometric methods using novel access to databases. 2) Establish a close link of the topical PhD projects to health policy and practice ensuring high relevance and practical applicability of results. Implementation of project results can potentially enhance performance of European health care systems. 3) Train PhD fellows to be experts in the field of quality of care and obtain excellent profiles for different career paths in health economic research or practice. 4) contribute to better coordination of currently fragmented health economic research in Europe. This will improve the competitive position of European health economic research. 5) serve as a model for joint doctorate programmes in health economics in Europe. This will drive the development of PhD programmes in health economics in Europe, which currently are scarce. To address these aims, the research programme consists of research clusters: (a) effectiveness & safety, (b) efficiency, (c) access & equitability, and (d) acceptability (WP2-5). Clusters also define secondments and joint research activities of one cluster. Across clusters, scientific training courses, soft-skill-courses and research-in-progress workshops will provide new skills and ensure interaction and exchange between PhD fellows (WP6). The strong participation of the non-academic sector in courses, workshops, acting as hosts, providing research data, or acting as practice mentors for PhD fellows will ensure transfer of research into practice (WP7).